Revenue +10.2% but NPAT just +2.5% as tax step-up and bigger equity base bite

That 3.8 percentage-point gap between PBT and NPAT growth is the cleanest read on what changed: operating performance improved more than the reported bottom line shows.

The balance sheet also expanded materially. Total assets grew 24% to NZ$7.4b and total equity grew 30.5% to NZ$1b, reflecting a capital raise during the comparable window. Operating cash flow swung from –NZ$142.3m to +NZ$262.2m, which for a lender largely reflects deposit and loan-book funding flows rather than an earnings-quality signal. The interim dividend was held flat at 5.5 cps.

• PBT grew 6.3% but NPAT grew only 2.5% because the effective tax rate moved up 270 basis points to 29.5%. Heartland itself flags an underlying NPAT of NZ$54.7m (+16.2%), implying roughly NZ$6m of one-off items absorbed by the reported number. For someone trying to read through to operating performance, PBT growth is the cleaner gauge, and PBT margin of 47.9% sits at the upper edge of Annolyse's historical range (mean 32.4%).
• Capital base outgrew earnings, diluting ROE. Equity expanded 30.5% while NPAT grew 2.5%, so ROE fell to 9.6% from 12.2%. The current 9.6% is still above the supplied historical baseline (4.5% mean, range 0.3%–7.8%), but the direction is weakening despite a strong margin print — the new capital has not yet been deployed at the prior return level.
• Asset growth is real, not cosmetic. A 24% lift in total assets, paired with a step-up in equity and the OCF inflow, points to balance-sheet-led growth (likely including the StockCo Australia acquisition referenced in FY22 commentary). This matters because revenue and PBT growth lag asset growth, which mechanically compresses returns until the new book seasons.

Using HY22 as a shape proxy, HY contributed 46.6% of FY22 revenue and 49.9% of FY22 NPAT, suggesting a modestly second-half-weighted pattern. Annualising HY23 net operating income at NZ$288.3m would already exceed FY22 (NZ$280.6m), and a similar 2H skew would push the full year materially higher.

The gap that matters is between strong reported margins and a softer NPAT/ROE trajectory. The release does not provide enough detail to assess whether the higher 29.5% tax rate is a new run-rate or period-specific, and that uncertainty directly affects how much of the underlying NZ$54.7m run-rate will translate into reported earnings in 2H.

Capex intensity remains modest at 5.4% of revenue. For a lender, the cash-flow swing reflects funding and loan-book dynamics, not earnings quality, so it should not be read as a working-capital tailwind to operating profit.

Two quality caveats temper the read. First, reported NPAT was reduced by roughly NZ$6m of disclosed one-offs that management excludes from underlying NPAT; the nature of those items is not visible in the supplied release excerpts. Second, the 270bp tax-rate step-up reduces the conversion of operating gains into shareholder earnings. Combined, these mean a meaningful share of the apparent NPAT softness is presentation- and tax-driven, not operational — but the dilution of ROE from the equity raise is a real economic effect that will only unwind as the larger asset base earns into prior return levels.

This briefing cannot assess the composition of the disclosed one-off items or the durability of the 29.5% effective tax rate without further disclosure from management.